Factors in Selecting IO Therapy for Patients With Advanced NSCLC
Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.
Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.
Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer
Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early
December 1st 2022Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.
Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC
Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
November 14th 2022Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.
New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders
August 5th 2022Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.
Montefiore Einstein Cancer Center Finds CAR T-Cell Therapy Effective in Black and Hispanic Patients
June 2nd 2022Investigators at the Montefiore Einstein Cancer Center report that Black and Hispanic patients had outcomes and side effects following CAR-T treatment that were comparable to their white and Asian counterparts, according to findings from a study published in Bone Marrow Transplantation.
Cancer Dormancy and Tumor Microenvironment Institute to Take Research Efforts to Greater Heights
October 29th 2021The Cancer Dormancy and Tumor Microenvironment Institute, which has recently been launched at Albert Einstein Cancer Center, will focus on taking the tumor microenvironment research being done at the center to the next level and to develop novel technologies that can better identify dormant cancer as well as prevent and control recurrent disease.
Focus on Health Equity in Cancer Care Leads to National Recognition
August 26th 2021Montefiore Einstein Cancer Center has once again earned national recognition for its quality of care studies leading to enhanced patient care, its strong cancer screening and early detection initiatives, and its exceptional support services.
Targeted Therapy Paradigm Grows in NSCLC, While Overcoming Resistance Represents Next Hurdle
June 29th 2021The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.
Lauren Hackett, MPA, to Lead Operations at NCI-Designated Albert Einstein Cancer Center
June 25th 2021Albert Einstein Cancer Center, Albert Einstein College of Medicine, and Montefiore Health System announced that Lauren Hackett, MPA, has been appointed the deputy director of administration of AECC and associate vice president of cancer medicine at Montefiore Medicine.
Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
June 24th 2021Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.